Business News • MarketWire • Adherex Reports Meeting With FDA's Pediatric Subcommittee of the Oncologic Drugs Advisory Committee on the Development of Sodium Thiosulfate Injection

Adherex Reports Meeting With FDA's Pediatric Subcommittee of the Oncologic Drugs Advisory Committee on the Development of Sodium Thiosulfate Injection

Adherex Reports Meeting With FDA's Pediatric Subcommittee of the Oncologic Drugs Advisory Committee on the Development of Sodium Thiosulfate Injection

RESEARCH TRIANGLE PARK, NC--(Marketwire - Oct 7, 2011) - Adherex Technologies Inc. (TSX: AHX) (PINKSHEETS: ADHXF), a biopharmaceutical company focused on cancer therapeutics, today announced that the FDA's Pediatric Subcommittee of the Oncologic Drugs Advisory Committee will discuss the development of Sodium Thiosulfate Injection, USP, 25% (STS) on November 1, 2011. STS is a chemoprotectant being developed to reduce or prevent hearing loss in children that can result from treatments utilizing platinum-based chemotherapy drugs. STS has received Orphan Drug Designation in the United States for the prevention of platinum-induced ototoxicity in pediatric patients. In addition, Adherex has licensed intellectual property rights for the use of STS as a chemoprotectant from Oregon Health & Science University.

View More : http://www.marketwire.com/mw/release.do?id=1570344&sourceType=3

Releted News by marketwire

BMO invite les Canadiens à acheter "local" et à encourager les fermes d'ici cette fin de semaine